Intertek Scales Capacity for Complex Drug Stability Testing
The company’s expanded stability storage hub now delivers a wide spectrum of ICH-compliant and ultra-low-temperature solutions, addressing growing needs for stability data and GMP analytical support across complex drug programs.
Global testing, inspection, and certification company, Intertek, has announced the expansion of its GMP pharmaceutical stability storage facility in Royston, near Cambridge, UK. Total capacity at the facility has increased to 625,000 liters, with the company now able to offer a wide range of storage solutions for the rapidly growing needs of pharmaceutical companies developing complex drug products (1).
Since its launch in 2015, the Royston facility has been expanded to offer a wider range of bespoke storage conditions in addition to all standard ICH temperature and relative humidity parameters, to position itself as one of Europe’s largest contract storage providers. The announcement coincides with the recent surge in innovative drug development programs that has driven unprecedented demand for stability storage paired with expert GMP analytical services.
For drug development, maintaining the stability and integrity of sensitive components is essential for delivering complex formulations, especially biologic drug products. Drug developers increasingly require diverse storage solutions — ranging from ultra-low-temperature facilities for cell-based materials at -80 °C and -150 °C to specialized environments for next-generation drug-device combination products — including critical components like single-dose plastic nebules used in nebulizer platforms for liquid inhalation therapies.
“This expansion cements our Royston facility as one of Europe’s largest and most advanced GMP pharmaceutical stability storage sites,” emphasized Olivier Coppey, President of Global Pharmaceutical Services at Intertek, when discussing the strategic importance of the investment in a company press release (1). “Combined with our teams’ outstanding expertise in analytical and formulation support, we help our clients mitigate risk and keep their challenging pharmaceutical development programs on track.”
"By offering pioneering standard and bespoke stability storage programs, fully integrated with expert formulation development and specialized analytical capabilities such as GMP-compliant combination drug product testing, our customers gain deeper product insight and stronger regulatory readiness,” highlighted Teresa Iley, Director of Pharmaceutical Development and Manufacture at Intertek, in the press release (1). “We continuously expand our GMP expertise to ensure precise characterization of purity, potency, identity and stability, supporting faster development of next-generation drug–device combination therapies.”
Intertek operates global ICH stability storage and testing locations in Manchester, UK, New Jersey, USA, and Melbourne, Australia, providing global CGMP contract analytical, bioanalytical, stability, and formulation support to the pharmaceutical sector. Intertek’s network spans more than 1,000 laboratories and offices across 100 countries, delivering assurance, testing, inspection and certification solutions that enable clients to operate safely with well-functioning supply chains.
Reference
Intertek. Intertek Expands one of Europe's Largest GMP Pharmaceutical Stability Storage Facilities to Meet Growing Customer Demand. Press Release, May 11, 2026.